Potential therapies currently in research and clinical phases for SARS‐CoV‐2 based on drug repurposing include remdesivir developed for EBOV disease [23], favipiravir for influenza and EBOV disease [24], chloroquine for malaria [25], and IL‐6 inhibitors tocilizumab and sarilumab for the treatment of rheumatoid arthritis [26]. Here, IL6 is linked to influenza.